TUKYSA
As listed in the register: TUKYSA
150 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Tucatinib
- Made by
- Pfizer Canada Ulc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (TUKYSA). It describes the substance, not this exact product.
Tucatinib is a tyrosine kinase inhibitor of HER2.
In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed anti-tumor activity in HER2 expressing tumor cells.
Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent via CYP3A.
Effects of Food Following administration of a single oral dose of TUKYSA in 11 subjects after a high-fat meal (approximately 58% fat, 26% carbohydrate, and 16% protein), the mean AUC 0-INF increased by 1.5-fold, the T max shifted from 1.5 hours to 4 hours, and C max was unaltered.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2024-11-04
Safety of the active substance
From the US prescribing label for the same active substance (TUKYSA). It describes the substance, not this exact product.
The most common adverse reactions (≥20%) with TUKYSA in combination with trastuzumab and capecitabine in patients with metastatic breast cancer are diarrhea, palmar-plantar erythrodysesthesia, nausea, hepatotoxicity, vomiting, stomatitis, decreased appetite, anemia, and rash.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Pfizer Canada Ulc |
|---|---|
| Active substance | Tucatinib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 150 mg |
| Form | tablet |
| Classification | L01EH03 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02499835 |
| DPD drug code | 98956 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products
- 50 mg
- 150 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.